Artelo Biosciences, a clinical-stage pharmaceutical company, reported nonclinical data showing its oral cannabinoid candidate ART27.13 produced weight loss comparable to Novo Nordisk’s semaglutide in obese mice. Over four weeks, each monotherapy reduced baseline body weight by approximately 20%, while the combination reduced weight by roughly 40%. About 80% of the weight lost with ART27.13 was fat, compared with 70% for semaglutide alone, and the combination delivered the largest improvements in cholesterol and glucose handling. ART27.13 is a potent full agonist of both CB1 and CB2 receptors designed to act primarily in peripheral tissues, contrasting with the historical focus on blocking CB1 receptors. The treatment did not affect weight, lean mass or fat mass in lean mice on a standard diet, while appetite returned over time in treated obese mice even as their lower body weights persisted.